GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genvec Inc (NAS:GNVC) » Definitions » Piotroski F-Score

Genvec (Genvec) Piotroski F-Score : 0 (As of Apr. 26, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Genvec Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Genvec has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Genvec's Piotroski F-Score or its related term are showing as below:


Genvec Piotroski F-Score Historical Data

The historical data trend for Genvec's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genvec Piotroski F-Score Chart

Genvec Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.00 3.00 5.00 2.00 1.00

Genvec Quarterly Data
Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.00 3.00 1.00 1.00 2.00

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar17) TTM:Last Year (Mar16) TTM:
Net Income was -1.195 + -1.207 + -1.525 + -4.273 = $-8.20 Mil.
Cash Flow from Operations was -1.805 + -1.177 + -1.232 + -2.797 = $-7.01 Mil.
Revenue was 0.026 + 0.173 + 0.022 + 0.114 = $0.34 Mil.
Gross Profit was 0.026 + 0.173 + 0.022 + 0.114 = $0.34 Mil.
Average Total Assets from the begining of this year (Mar16)
to the end of this year (Mar17) was
(7.647 + 10.526 + 9.268 + 7.707 + 4.906) / 5 = $8.0108 Mil.
Total Assets at the begining of this year (Mar16) was $7.65 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $4.59 Mil.
Total Current Liabilities was $2.20 Mil.
Net Income was -1.869 + -1.505 + -1.642 + -1.86 = $-6.88 Mil.

Revenue was 0.127 + 0.193 + 0.16 + 0.29 = $0.77 Mil.
Gross Profit was 0.127 + 0.193 + 0.16 + 0.29 = $0.77 Mil.
Average Total Assets from the begining of last year (Mar15)
to the end of last year (Mar16) was
(13.679 + 12.188 + 10.852 + 9.463 + 7.647) / 5 = $10.7658 Mil.
Total Assets at the begining of last year (Mar15) was $13.68 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $7.30 Mil.
Total Current Liabilities was $1.53 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Genvec's current Net Income (TTM) was -8.20. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Genvec's current Cash Flow from Operations (TTM) was -7.01. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar16)
=-8.2/7.647
=-1.07231594

ROA (Last Year)=Net Income/Total Assets (Mar15)
=-6.876/13.679
=-0.50266832

Genvec's return on assets of this year was -1.07231594. Genvec's return on assets of last year was -0.50266832. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Genvec's current Net Income (TTM) was -8.20. Genvec's current Cash Flow from Operations (TTM) was -7.01. ==> -7.01 > -8.20 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar17)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar16 to Mar17
=0/8.0108
=0

Gearing (Last Year: Mar16)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar15 to Mar16
=0/10.7658
=0

Genvec's gearing of this year was 0. Genvec's gearing of last year was 0. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar17)=Total Current Assets/Total Current Liabilities
=4.593/2.195
=2.09248292

Current Ratio (Last Year: Mar16)=Total Current Assets/Total Current Liabilities
=7.297/1.534
=4.75684485

Genvec's current ratio of this year was 2.09248292. Genvec's current ratio of last year was 4.75684485. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Genvec's number of shares in issue this year was 2.274. Genvec's number of shares in issue last year was 1.726. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0.335/0.335
=1

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0.77/0.77
=1

Genvec's gross margin of this year was 1. Genvec's gross margin of last year was 1. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar16)
=0.335/7.647
=0.04380803

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar15)
=0.77/13.679
=0.05629066

Genvec's asset turnover of this year was 0.04380803. Genvec's asset turnover of last year was 0.05629066. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+1+0+0+0+0
=2

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Genvec has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

Genvec  (NAS:GNVC) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Genvec Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Genvec's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Genvec (Genvec) Business Description

Traded in Other Exchanges
N/A
Address
Genvec Inc was incorporated under the laws of the state of Delaware on December 7, 1992.The Company is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. Its development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus or RSV, herpes simplex virus or HSV, and malaria. In the area of animal health the Company is developing vaccines against foot-and-mouth disease or FMD. In collaboration with Novartis, the Companys hearing and balance disorders program is focused on the restoration of hearing and balance function through the regeneration of critical cells of the inner ear. The Company is currently developing preventative vaccines, against RSV and malaria and therapeutic vaccine against HSV.
Executives
Wayne T Hockmeyer director ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Michael Richman director 2635 TECHNOLOGY FOREST BLVD., HOUSTON TX 77381
Marc R Schneebaum director GENVEC, INC., 65 WEST WATKINS MILL ROAD, GAITHERSBURG MD 20878
Stefan Loren director 3226 AVENIDA DE SUENO, CARLSBAD CA 92009
Douglas J Swirsky director, officer: President and CEO C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD 20850
Willam N Kelley director MERCK & CO., INC., ONE MERCK DRIVE, WHITEHOUSE STATION X1 08889
Mmcap International Inc. Spc 10 percent owner C/O MOURANT GOVERNANCE SVCS (CAYMAN) LTD, 94 SOLARIS AVE., CAMANA BAY, PO BOX 1348, GRAND CAYMAN E9 KY1-1108
Ecor1 Capital Fund Qualified, L.p. other: See Explanation of Responses 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Capital, Llc 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Oleg Nodelman 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Capital Fund, L.p. other: See Explanation of Responses 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Zola P Horovitz director C/O GENAERA CORP, 5110 CAMPUS DDRIVE, PLYMOUTH MEETING PA 19462
Cynthia Collins director, officer: President & CEO 65 WEST WATKINS MILL ROAD, GAITHERSBURG MD 20878
Adel Mahmoud director
Joshua Ruch director 4 DUNE ROAD, EAST QUOGUE NY 11942

Genvec (Genvec) Headlines

From GuruFocus

GenVec Inc. Reports Operating Results (10-Q)

By gurufocus 10qk 05-07-2010

GenVec Inc. Reports Operating Results (10-Q)

By gurufocus 08-07-2009

GenVec Inc. Reports Operating Results (10-K)

By gurufocus 10qk 03-11-2011

GenVec Inc. Reports Operating Results (10-Q)

By gurufocus 10qk 11-06-2009

GenVec Inc. Reports Operating Results (10-Q)

By gurufocus 05-08-2009